Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Targeting the brain might help patients with respiratory disorders

Targeting the brain might help patients with respiratory disorders

The brain may be a new therapeutic target for improving breathing following lung injury in COVID-19 patients, according to study in rats

New research published in The Journal of Physiology suggests that lung injury is not limited to the lungs. Targeting the part of the brain that controls breathing and blood flow might help patients with respiratory disorders, such as lung injury due to COVID-19, and speed the process of weaning patients from mechanical ventilators.

With respiratory infections like COVID-19 or other pulmonary infections, activation of the immune system is part of the normal, healthy response. However, in some cases the inflammatory response is so powerful that it leads to further lung damage called acute lung injury (ALI) and in its most severe form acute respiratory distress syndrome (ARDS). Typical clinical care of patients with ALI and ARDS is focused on minimizing further lung damage using specialised forms of mechanical ventilation.

This new study suggests that the injury is not limited to the lungs, but may also have a lasting impact on the central control of respiration. Thus, targeting the parts of the brain that regulate our breathing might be an important therapy for weaning patients from ventilatory support following their recovery from severe respiratory infections, ALI and ARDS. This is important to understand during the COVID-19 pandemic as these patients may experience the same difficulties transitioning to breathing on their own.

Currently, ALI and ARDS therapy focuses on the lungs to maintain gas exchange and minimize further injury.  These researchers examined rats with lung injury and determined that the brain regions that control breathing are affected also. In fact, the characteristics of the pathologic breathing pattern remain even when the lungs are removed. In addition, inflammation was evident in the part of the brain that generates the breathing pattern. This indicates that the lungs are not the only factor involved in breathing disorders in lung injury.

These scientists then examined what happens in conscious lung injured rodents when they introduced non-steroidal anti-inflammatory drugs within the central nervous system. They found that this treatment reduced neural inflammation and minimized the effects of lung injury. These findings suggest that brainstem circuits play a role in the pathophysiology and potential recovery of the respiratory system following lung injury and ARDS.

Commenting on the study, first author Yee-Hsee Hsieh said:

“Clinical treatment for respiratory illnesses typically focuses on adopting ventilatory protocols that protect the lung from further lung injury and current research focuses on repair and restoration of pulmonary tissue and function. This study suggests we also need to address the role of the central nervous system and neuro-inflammation to completely treat acute lung injury and perhaps other lung diseases like COVID-19.”

New software eases coronavirus testing burden for health organization

New software eases coronavirus testing burden for health organization

Experts say, the rate of testing for coronavirus needs to increase rapidly, at a proposed increase of 200%, if we hope to safely end stay-at-home orders and open up the economy. In the efforts to ramp up, chaos and disorganization are hitting testing sites from Kentucky to LA to Hard Rock Stadium. Nationwide, hundreds of individuals per testing site are spending hours in line, without guarantee, for a limited number of available tests.

Who’s affected: These bottlenecks can be excruciating for those who need to be tested the most, primarily the sick and elderly. Healthcare workers are utilizing personnel and resources to organize this chaos, who could otherwise be focusing their efforts on caring for patients.

Solution: Technology company Skedulo has developed the first widespread tool, free of charge, for COVID-19 testing centers to schedule and organize testing, ending long patient queues and overbooking. Though the concept and technology isn’t revolutionary, it’s exactly what’s needed to make an immediate difference.

The “Capacity-Based Appointment Booking” software application is a management system for organizations who are running multi-site COVID-19 testing centers, including drive-through testing facilities. It will be available to any facility on the Salesforce marketplace to help efficiently manage testing requests, have visibility into booking vs capacity as well as triage appointments. It allows the public to search for available scheduling sites, book appointments in advance, and go through a contactless check in.

Ecolog and GE Healthcare in Germany Signed a MOU to Join Forces in Combating COVID-19 Pandemic

Ecolog and GE Healthcare in Germany Signed a MOU to Join Forces in Combating COVID-19 Pandemic

ECOLOG International, a leading global provider of integrated services, technology, environmental solutions, energy, logistics, engineering and construction and GE Healthcare in Germany, a leading manufacturer and supplier of medical technologies, digital infrastructure, data analytics and advance decision support tools, join forces in addressing COVID-19 pandemic.

Rapid Care Park™ – part of Ecolog’s Eco-Care Solution – will provide end-to-end relief and recovery services including flexible ICU and care capacity to reduce the load on the healthcare system as the countries navigate the waves and allow hospitals and clinics to allocate the “clean capacity” to essential operations.

GE Healthcare’s broad range of medical equipment including ventilators, X-ray units and CT scans are amongst the key pieces of apparatus used in medical facilities such as Ecolog’s Rapid Care Park.

Commenting on the agreement, Ali Vezvaei, Group CEO of Ecolog International said, “In the face of current global challenges caused by the Covid-19 pandemic, we at Ecolog continue doing everything in our power to help the public and private sectors in relief and recovery. And in doing so we are pleased to work with a reliable medical equipment and technology providers like GE Healthcare. The collaboration will enhance our services to our clients.”

Catherine Estrampes, CEO of GE Healthcare Europe mentioned: “As the world navigates the unprecedented challenge presented by the COVID-19 pandemic, we at GE Healthcare are honored to help support Healthcare Providers, communities, and patients around the world.

Michael Stockhammer, Managing Director of GE Healthcare (DACH) further added: “Leveraging our equipment and expertise, we believe we can help accelerate these efforts to address the pandemic and provide the much-needed flexible capacity.”

Medtronic Gives $1 Million in Product Donations to Insulin for Life to Support COVID-19 Relief Efforts

Medtronic plc, the global leader in medical technology, announced a $1 million product donation to Insulin for Life USA to support COVID-19 relief efforts. Medtronic will donate sensors, infusion sets and reservoirs, which will be distributed by Insulin for Life USA to patients on insulin pump therapy experiencing financial hardships as a result of COVID-19.

Insulin for Life USA, with support from the Leona M. and Harry B. Helmsley Charitable Trust, will provide these supplies to approximately 15 diabetes clinics across the U.S. that serve people in need living with type 1 diabetes. Insulin for Life USA is a non-profit that supports continuity of therapy for people living with diabetes who otherwise would go without these critical and often life-saving supplies.

“Our hearts go out to all those who are suffering losses due to this pandemic. We know how challenging this situation has been on the diabetes community given the uncertainty that it brings — particularly to those experiencing job losses or financial hardships as a result of this situation,” said Sean Salmon, president for the Diabetes Group at Medtronic. “Concerns about continuity of therapy create an additional layer of anxiety during a time that is already stressful, and we hope these contributions will provide some relief to those who need it most during this truly difficult time.”

This donation to Insulin for Life USA expands on Medtronic’s holistic philanthropic efforts that focus in part on continuity of therapy initiatives through ongoing product and monetary donations to non-profit organizations including CR3 Diabetes Association, Inc., Diabetes Will’s Way, and American Board for Child Diabetics. In addition to these efforts, Medtronic employees are encouraged to give back to the communities in which they live and work through volunteer hours and charitable contributions, which are now matched 2:1 through the Medtronic Foundation to amplify the impact of these donations where employees feel the need is greatest. The company match was increased earlier this month to elevate the COVID-19 response, empowering Medtronic employees to identify local needs and direct resources to their communities.

“We recognize that this is a time of great need across many communities and we are leaning in to offer support where we can. This includes developing an inclusive offering of programs to assist customers experiencing hardships. We are encouraging customers that need this additional support to leverage the flexible payment plans and financial assistance programs we offer,” said Salmon. “Our teams are committed to supporting our customers with the empathy and compassion they need at this time given how much they entrust us with their diabetes management needs.”

About the Diabetes Group at Medtronic
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

CheckedUp Launches Virtual Visits, Advanced Telehealth Platform for Specialty Care

CheckedUp Launches Virtual Visits, Advanced Telehealth Platform for Specialty Care

CheckedUp the fastest growing specialty medicine digital point of care company announced the launch of CheckedUp Virtual Visits, an innovative, advanced telemedicine system designed to redefine virtual specialty care.

CheckedUp Virtual Visits, designed by physicians for physicians, was created to keep patients and physicians at the center of pivotal healthcare decisions as “point of care” engagement evolves with patient needs and becomes increasingly digital. As the COVID-19 pandemic continues to alter the world’s “new normal,” CheckedUp is proud to offer a valuable, innovative service that redefines the virtual consultation experience. Its innovative platform empowers specialty care physicians, patients, and industry partners in multiple, dynamic ways.

“From early on, our leadership team viewed the COVID-19 crisis as an unprecedented challenge requiring an innovative response,” said Mark Goethals, Vice President of Marketing, CheckedUp. “Our efforts are focused on a new, post-COVID healthcare delivery landscape, delivering the service and functionality of a virtual examination room to patients and enabling providers to deliver superior virtual patient care. CheckedUp Virtual Visits allows physicians to meet their patients when and where they are, while providing innovative tools for providers and patients during their digital consultation. We are also happy to extend that accessibility to our partners in the life sciences, so that they can be a part of tomorrow’s healthcare conversations.”

CheckedUp Virtual Visits offers distinct care advantages over traditional telemedicine systems. It simplifies scheduling and operations, allows patients to see the dedicated specialist they know and trust, and brings the same easy to use technologies physicians use in the physical exam room, into the virtual realm.

“CheckedUp Virtual Visits leads a new era in the way physicians engage with patients during virtual consultations,” said Dan Schwartz, Senior Vice President, Sponsorship Sales, CheckedUp. “Current telemedicine systems, while serving an important role today, offer very little by way of additional in-office technologies, making exceptional care possible. We expect to change that.”

CheckedUp Virtual Visits is designed to perfectly replicate the patient and physician experience in a virtual setting, streamline administrative efforts by tracking physicians’ personal notes and information regarding every consult, and remain HIPAA Compliant.

About CheckedUp

CheckedUp is one of New York’s fastest growing healthcare technology growth companies and is the only 100% digital, push technology platform designed for specialty point of care. CheckedUp has deployed a state-of-the-art platform into Specialty Healthcare facilities across the United States to actively engage patients, caregivers, and physicians in the waiting room, exam room, and at home. As a healthcare technology leader, CheckedUp aspires to create better educated and more confident patients and physicians who are empowered to make better health decisions together. CheckedUp was ranked #279 on Inc. 5,000’s list of the Fastest Growing Private Companies in the US.

Is It Safe To Do Baby Circumcision During COVID-19?

Safe To Do Baby Circumcision During COVID-19

Circumcising babies is a common practice in many countries and cultures. Babies may be circumcised due to the religious beliefs of the parents and/or guardians or for medical or health reasons. However, if you are concerned about circumcising your newborn because of the ongoing COVID-19 pandemic, this is a valid fear. Many parents and/or guardians of newborns are quite concerned about this.

If you want to know whether your newborn should be circumcised, no worries. This article summarizes some key points so that you are more informed about what circumcision is and how this minor surgical procedure is done. Then you are better able to decide if your child should be circumcised at this time.

What is Circumcision?

Circumcision is a surgical procedure done to remove the foreskin of the penis of a male. The procedure is often done on newborns as requested by the parents and/or guardians of the newborn child for religious reasons, or by other individuals for medical, health, or aesthetic reasons. Jews and Muslims are the usual religious groups that request this surgical procedure on their newborns, usually from 1 to 2 days after birth.

Why Is Circumcision Necessary?

Circumcision can be done on a male newborn infant for health reasons, or as mentioned, for cultural or traditional beliefs. In terms of health, circumcised males are believed to have a lower risk of developing sexually transmitted diseases such as HIV, herpes, or gonorrhea. In addition, a circumcised male can also have some protection from cancer of the penis. At the same time, these benefits are not limited to male infant circumcisions; even adult circumcision can have the same effects.

However, in countries such as the US or Canada, circumcision is deemed an elective procedure, which means that doctors do not consider this as necessary at all. There is an increasing decline of male infant circumcision in the UK, Canada, Ireland, and Australia but an increasing demand in South Africa. Generally, however, some 80% of the world’s countries have never practiced male infant circumcision. These include the USSR, China, Japan, Austria, France, Switzerland, and Germany.

Will the Newborn Be At Risk of COVID-19 Infection if Circumcised? 

Before you agree to male newborn circumcision, it is always a good idea to look for a hospital or clinic such as Circumcision Manchester. You should check that all services and procedures are guaranteed clean and sterile. At the same time, you should check that a doctor who is experienced in newborn circumcision procedure is available.

You can also check information online or from the City Hall that has jurisdiction over the location of the hospital or clinic to see if it is a hub for COVID-19 infections. If there is no word yet about which locations are a hub for COVID-19 infections in your community, you may defer the circumcision until after the risk of COVID-19 spreading in your neighborhood has tapered off.

How to Protect Your Newborn from COVID-19 Infection

To lessen the risk of COVID-19 infection even before the newborn is circumcised, it is important for the parents and/or guardian of the infant to be careful about going out of the home of the child since they may become asymptomatic carriers of the virus. If you want to ensure the health of your newborn, keep the child away from visitors, even if they are family members. At the same time, have yourself and your spouse as well as those living in your home tested for possible COVID-19 infection.

Here are some key pointers on how you can prevent the spread of COVID-19 to your newborn:

  • The home of the child should be kept as clean and sterile as possible, with emphasis on the nursery or the room where the child will be staying.
  • Everyone should always wear a clean new surgical mask and always disinfect their hands with soap and water so that they won’t pass on any pathogens or viruses to the child.
  • Take a shower every day and wear clean clothes before you attempt to change or feed your infant.
  • You can rely on videos taken through your cellphone to keep other family members updated about what is happening within the nursery if they really need to know.
  • If you do have to leave the house for some reason, you should make it a point to disinfect your entire body, your shoes, bags, and particularly your hair and clothes before venturing back into the house. Remember to maintain your house as a “clean zone” so that you won’t bring in the virus into your home.
  • If you go out shopping, disinfect every package that you bring into the house.
  • Always wear clean clothes and indoor slippers or shoes after you have disinfected yourself.
  • Make sure that used clothes and shoes are disinfected right away.
  • Monitor the health of other family members as well. If anyone seems to be developing signs of COVID-19 infection, have them tested then isolated for 14 days in their own room. Make sure they do not leave their room until the 14 days are over, but not before the test results come back negative.
  • If the family member tests positive for the COVID-19 infection, it is best to keep that family member in their room with absolutely zero contact with other members of the household. Make sure and observe if that person develops advanced signs of the COVID-19 infection.
  • Make sure to follow the quarantine rules strictly. You should try and stay within the nursery or baby’s room 24/7 so that you can closely observe your newborn for any signs of illness.

Takeaways 

It is good to acknowledge the possibility that your newborn can get exposed to the COVID-19 virus somehow, particularly if the newborn is supposed to be circumcised. It is more important to protect your newborn from viral exposure than to rush a traditional or religious ritual. Bringing your child out of the house for a circumcision seems unwise at this point when the pandemic is still ongoing. You should defer the circumcision, preferably after health authorities have cleared your community from the list of COVID-19 hotspots. These steps can help protect your newborn from possible viral infection.

Roche’s SARS-CoV2 antibody test will help evaluate the patients immune response to the virus

Roche's SARS-CoV2 antibody test will help evaluate the patients immune response to the virus

Roche has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its new Elecsys Anti-SARS-CoV-2 antibody test.

Elecsys Anti-SARS-CoV-2 is an immunoassay for the in-vitro qualitative detection of antibodies to severe acute SARS-CoV-2 in human serum and plasma. The test has been developed to determine a person whether he is exposed to the SARS-CoV-2 virus, as well as developed antibodies against SARS-CoV-2.

The company has already commenced distributing the new antibody test to major laboratories across the globe. It will also increase the production capacity to high double-digit millions per month to serve healthcare systems even in the countries accepting the CE mark.

Roche Group CEO Severin Schwan said: “Thanks to the enormous efforts of our dedicated colleagues we are now able to deliver a high-quality antibody test in high quantities, so we can support healthcare systems around the world with an important tool to better manage the COVID-19 health crisis.”
Roche’s SARS-CoV2 antibody test has specificity greater than 99.8% and sensitivity of 100%

With a specificity of over 99.8% and 100% sensitivity, Roche’s SARS-CoV2 antibody test help to evaluate the immune response to the virus. Roche’s cobas e analysers are used to run the test, which is widely available for hospitals and reference laboratories across the world.

The test, which is based on an in-solution double-antigen sandwich format, can identify antibodies to the new coronavirus causing COVID-19. Elecsys Anti-SARS-CoV-2 assay has 99.81% specificity based on the measurement of a total of 5272 samples.

Elecsys Anti-SARS-CoV-2 helps to identify antibodies with 100% sensitivity in samples taken 14 days after a PCR-confirmed infection. Roche holds the capacity to deliver high double-digit millions of tests per month, with advanced global manufacturing capabilities.

Roche Diagnostics CEO Thomas Schinecker said: “Roche is committed to helping laboratories deliver fast, accurate, and reliable results to healthcare professionals and their patients.”

India’s mobile coronavirus testing van hits New Delhi streets

India's mobile coronavirus testing van hits New Delhi streets

The battle against COVID-19 in Delhi is on war footing with a number of measures being taken to curb the spread of the coronavirus COVID-19. However, the key to fight this pandemic is testing, tracing and treatment. So, the District Magistrate of Delhi’s Central District launched a COVID-19 testing machine on wheel.

“It was important to make testing viable, accessible and at the same time ensuring safety of health workers. Therefore, Central District has initiated the ‘TESTING OF COVID-19 ON WHEELS’ which shall cover the length and breadth of lanes and bylanes of Delhi,” said Nidhi Shrivastav DM Central District.

The vehicle will be able to cater to narrow lanes, larger and dense areas of District Central, increasing the number of samples collected in a day. The mobile van can collect two samples at a time. It will take both nasopharyngeal and oropharyngeal swabs, seal them tight in double packing and transfer the sample to the testing facility.

The vehicle is fitted with an inverter, an ice box to keep the samples intact. The mobile van is attached with a speaker to make announcements as it goes on rounds.

It will not only save time but also the people who are collecting the samples. The person who will collect the sample will be in the enclosure, so will not have to wear PPE.

Delhi’s Central District has been severely affected by the pandemic and has seven containment zones.

 

3M and Ford Begin Shipping Newly Designed Powered Air-Purifying Respirators for Health Care Workers Fighting COVID-19

3M and Ford Begin Shipping Newly Designed Powered Air-Purifying Respirators for Health Care Workers Fighting COVID-19

Newly designed powered air-purifying respirators (PAPRs), developed by Ford in close collaboration with 3M, are on the way to health care workers fighting COVID-19.

Since late March, the companies have been working rapidly to design and deliver urgently needed PAPRs, drawing on 3M’s expertise in personal safety equipment, technology and regulatory requirements. Through the collaboration, 3M and Ford brought the new PAPR from idea to product in 40 days. Now, more than 10,000 of the newly designed PAPRs are ready to be shipped from Ford’s Vreeland facility near Flat Rock, Michigan.

“We are dedicated to helping support and protect the health care workers fighting COVID-19,” said Bernard Cicut, vice president, 3M Personal Safety Division. “We thank Ford for partnering with us to quickly develop and deliver more of these critical health care supplies to the heroes working on the frontlines of this unprecedented health crisis.”

3M is a leading provider of personal protective equipment, including powered air-purifying respirators. Demand for 3M PAPRs is exceeding supply due to the COVID-19 pandemic. Through partnerships with companies like Ford and Cummins, 3M plans to increase capacity of its own PAPRs by ten-fold within the next several months.

“Ford could not stand by while health care workers in this country placed their lives on the line to help others without even having proper protection,” said Jim Baumbick, vice president, Ford Enterprise Product Line Management. “That’s why we kicked off an all-out sprint to protect those who are so selflessly helping patients afflicted with this terrible virus.”

The Ford Limited-Use Public Health Emergency PAPR includes a hood and face shield to cover health care professionals’ heads and shoulders, while a high-efficiency (HEPA) filter system provides a supply of filtered air for up to eight hours on a single battery charge. The air blower system—built around fan components found in Ford F-150’s ventilated seats—is powered by a rechargeable, portable battery, helping keep the respirator in constant use by first-line defenders.

The 3M and Ford development team worked closely with the U.S. Centers for Disease Control and Prevention’s (CDC) NIOSH National Personal Protective Technology Laboratory. NIOSH provided timely guidance to encourage the development of PAPRs to help respond to the COVID-19 emergency. NIOSH has issued temporary approval under its limited-use protocol to respond to the COVID-19 public health emergency.

3M will sell and distribute the newly designed Ford Limited-Use Public Health Emergency PAPR through select 3M-authorized U.S. distributors to quickly and efficiently deploy these technologies to health care workers. The company will also provide technical support for health care workers using the new PAPRs. These 3M-authorized distributors moved exceptionally fast to make the PAPRs available for order within days.

3M and Ford will donate any profits they earn from the sale of the PAPR to COVID-19 related nonprofit organizations.

Since the initial outbreak, 3M has doubled its global output of filtering facepiece respirators, such as N95s, to a rate of more than 1.1 billion per year, or nearly 100 million per month. In the United States, 3M is producing 35 million N95 respirators per month, with more than 90 percent going to health care workers. 3M has already put into motion investments and actions that will enable it to double its N95 and other filtering facepiece respirator capacity once again to two billion globally within the next 12 months.

Invicro LLC to Establish a Repository of Medical Image Datasets for COVID-19 Research

Invicro LLC to Establish a Repository of Medical Image Datasets for COVID-19 Research

Invicro LLC, is working with Microsoft to create a free repository of COVID-19 diagnostic CT and X-ray datasets to facilitate understanding and treating this global threat. The repository uses the advanced technologies in Invicro’s iPACS® and the Microsoft Azure cloud platform, offering the required security, privacy, and compute power. This critical mission invites and strongly encourages researchers worldwide to access the data and to contribute COVID-19 images and clinical data.

Early partner in this effort includes Johns Hopkins University (USA) and other leading medical institutions are emerging. Partnership with Johns Hopkins would include developing advanced algorithms for feature detection of pulmonary pathology in preclinical models. In addition, the World Molecular Imaging Society will provide access to its extensive network to promote involvement and encourage alignment with the mission.

“First and foremost, on behalf of all of Invicro, our thoughts go out to those who have succumbed to this fatal pandemic and their loved ones, and our appreciation and admiration goes out to all the healthcare providers and first responders,” stated Dr Matthew Silva, Chief Executive Officer of Invicro. “Invicro is honored to partner with Microsoft, a global leader in computing systems, and major medical institutions to help phenotype and eradicate COVID-19.”

As research evolves daily to uncover treatments for this serious disease, scientists and physicians have turned to CT and X-ray biomarkers to better understand COVID-19 disease presentation, progression, and response to therapy. However, there are limited resources for researchers and data scientists to advance analytical tools specific to the presentation and progression of COVID-19. This growing database is intended to address this critical bottleneck.

“COVID-19 has united so many organizations to fight for a common cause,” said Heather Jordan Cartwright, GM, Microsoft Health. “The images and metadata being captured during this medical pandemic are essential for research. Microsoft is partnering with Invicro and other healthcare leaders to enable a highly secure and private data platform that can rise to the challenge of this global initiative.”

The “COVID iPACS Data Repository” uses Invicro’s iPACS® web-based data management platform and is hosted on Azure. The system will offer automated anonymization and quality control of all incoming data as well as be compliant with GDPR, EU Data Privacy Shield to ensure patient privacy and data protection standards are in line with regulatory guidelines.

“It is more critical than ever to commit to science and research for the welfare of human life,” commented Kiyotaka Fujii, President of Konica Minolta Global Healthcare and Chairman & CEO of Konica Minolta Precision Medicine. “The strength of imaging to provide detailed visualization, characterization, and quantification of pathological processes combined with AI-analysis from CT and X-ray data sets can improve diagnosis as well as treatment planning and will accelerate discovery and development of drug treatments for COVID-19. We are proud to work with Microsoft to offer this service.”

About Invicro

Headquartered in Boston, MA, Invicro was founded in 2008 with offices, laboratories and clinics around the world, from coast-to-coast within the United States, to Europe and Asia that support leading pharmaceutical and biotechnology and top research universities. Invicro’s multi-disciplinary team provides solutions to help enhance the discovery and development of life-changing drugs across all stages of the drug development pipeline (Phase 0-IV), leveraging all modalities within a broad scope of therapeutic areas, including neurology, oncology, cardiology, and immunology. Invicro’s quantitative biomarker services, advanced analytics tools, and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant® and iPACS®.

Invicro is a Konica Minolta company and part of their precision medicine initiative, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. Along with their sister company, Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics.

About Konica Minolta

Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nanofabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries.

1...619620621...1,125Page 620 of 1,125

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »